Investigational drugs for the treatment of cervical cancer.
about
Bauhinia variegata candida Fraction Induces Tumor Cell Death by Activation of Caspase-3, RIP, and TNF-R1 and Inhibits Cell Migration and Invasion In Vitro.Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 in vitro and in vivo.Luteoloside Inhibits Proliferation and Promotes Intrinsic and Extrinsic Pathway-Mediated Apoptosis Involving MAPK and mTOR Signaling Pathways in Human Cervical Cancer Cells.Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.Influence of Phosphatidylinositol-3-Kinase/Protein Kinase B-Mammalian Target of Rapamycin Signaling Pathway on the Neuropathic Pain Complicated by Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection
P2860
Investigational drugs for the treatment of cervical cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Investigational drugs for the treatment of cervical cancer.
@en
Investigational drugs for the treatment of cervical cancer.
@nl
type
label
Investigational drugs for the treatment of cervical cancer.
@en
Investigational drugs for the treatment of cervical cancer.
@nl
prefLabel
Investigational drugs for the treatment of cervical cancer.
@en
Investigational drugs for the treatment of cervical cancer.
@nl
P2093
P2860
P50
P1476
Investigational drugs for the treatment of cervical cancer
@en
P2093
Domenica Lorusso
Francesco Raspagliesi
Giorgio Bogani
P2860
P304
P356
10.1080/13543784.2017.1302427
P407
P577
2017-03-08T00:00:00Z